IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
40.11
-1.66 (-3.97%)
Aug 28, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 234.13 | 218.71 | 7 | 23.39 | 50.93 | 27.94 | |
Revenue Growth | 3244.67% | 3024.43% | -70.07% | -54.09% | 82.28% | 43.01% |
Cost of Revenue | 319.36 | 314.7 | 294.67 | 129.51 | 89.54 | 58.16 |
Gross Profit | -85.24 | -95.99 | -287.67 | -106.12 | -38.61 | -30.22 |
Selling, General & Admin | 77.07 | 63.32 | 39.3 | 28.31 | 23.9 | 20.05 |
Research & Development | 54.64 | - | - | - | - | - |
Operating Expenses | 131.72 | 63.32 | 39.3 | 28.31 | 23.9 | 20.05 |
Operating Income | -216.95 | -159.31 | -326.98 | -134.43 | -62.5 | -50.27 |
Interest & Investment Income | 31.96 | 35.64 | 29.27 | 9.92 | 3.15 | 2.34 |
EBT Excluding Unusual Items | -185 | -123.67 | -297.71 | -124.51 | -59.35 | -47.93 |
Gain (Loss) on Sale of Investments | 9.98 | 9.98 | 23.23 | 11.55 | 0.7 | -1.83 |
Pretax Income | -175.02 | -113.7 | -274.48 | -112.96 | -58.66 | -49.76 |
Net Income | -175.02 | -113.7 | -274.48 | -112.96 | -58.66 | -49.76 |
Net Income to Common | -175.02 | -113.7 | -274.48 | -112.96 | -58.66 | -49.76 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 89 | 88 | 82 | 58 | 41 | 35 |
Shares Outstanding (Diluted) | 89 | 88 | 82 | 58 | 41 | 35 |
Shares Change | 2.12% | 8.33% | 42.00% | 38.79% | 17.57% | 42.60% |
EPS (Basic) | -1.96 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 |
EPS (Diluted) | -1.96 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -113.87 | -73.47 | -251.44 | -117.59 | -90.62 | -58.42 |
Free Cash Flow Per Share | -1.27 | -0.83 | -3.08 | -2.04 | -2.19 | -1.66 |
Gross Margin | -36.41% | -43.89% | - | - | -75.80% | -108.15% |
Operating Margin | -92.66% | -72.84% | -4671.07% | -574.85% | -122.72% | -179.91% |
Profit Margin | -74.75% | -51.99% | -3921.10% | -483.05% | -115.17% | -178.10% |
Free Cash Flow Margin | -48.64% | -33.59% | -3592.01% | -502.85% | -177.92% | -209.09% |
EBITDA | -214.2 | -156.61 | -324.59 | -131.95 | -60.4 | -48.54 |
EBITDA Margin | -91.49% | -71.61% | - | - | -118.59% | -173.73% |
D&A For EBITDA | 2.76 | 2.7 | 2.39 | 2.48 | 2.1 | 1.73 |
EBIT | -216.95 | -159.31 | -326.98 | -134.43 | -62.5 | -50.27 |
EBIT Margin | -92.66% | -72.84% | - | - | -122.72% | -179.91% |
Revenue as Reported | 234.13 | 218.71 | 7 | 23.39 | 50.93 | 27.94 |